Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ametinib plus icotinib in EGFR-mutant advanced non-small cell lung cancer with brain metastases
ChiCTR2100044216Phase 2Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- May 2021
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of imatinib and icotinib in non-small cell lung cancer (NSCLC) (3 arms), sponsored by West China Hospital of Sichuan University. Primary endpoints: Maximum tolerated dose and Number and proportion of patients who can complete 6 treatment cycles. Started May 2021; status: recruiting.
02
Drugs
imatinibicotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2100044216.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100044216.